Orexigen overhauls management and cuts pipeline
This article was originally published in Scrip
Executive Summary
Orexigen Therapeutics is narrowing its focus to its late-stage pipeline after shelving the development of two mid-stage obesity candidates. The company will also shakeup its senior management with four executives scheduled to leave.